@commieserenity Technically they are in a quiet period with the quarter ending this week but given the analyst is quoting the company they need to respond.
@JonahLupton $TMDX has the most catalysts in the next 12-18 months with trials, studies, kidneys, Europe. 3X in 18 months $RDDT is most undervalued based on large cap growth metrics including huge gross margins, growth and earnings stock 2.5X in 18 months.